» Sign in / Register

Gemcitabine-5'-triphosphate

Sodium Salt

2',2'-Difluorocytidine-5'-triphosphate, Sodium salt

Cat. No. Amount Price (EUR) Buy / Note
NU-1607S 50 μl (10 mM)157,60 Add to Basket/Quote Add to Notepad
NU-1607L 5 x 50 μl (10 mM)461,70 Add to Basket/Quote Add to Notepad
Structural formula of Gemcitabine-5'-triphosphate (Sodium Salt, 2',2'-Difluorocytidine-5'-triphosphate, Sodium salt)
Structural formula of Gemcitabine-5'-triphosphate

For general laboratory use.

Shipping: shipped on gel packs

Storage Conditions: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Shelf Life: 12 months after date of delivery

Molecular Formula: C9H14N3O13P3F2 (free acid)

Molecular Weight: 503.14 g/mol (free acid)

Exact Mass: 502.97 g/mol (free acid)

Purity: ≥ 95 % (HPLC)

Form: solution in water

Color: colorless to slightly yellow

Concentration: 10 mM - 11 mM

pH: 7.5 ±0.5

Spectroscopic Properties: λmax 271 nm, ε 9.1 L mmol-1 cm-1 (Tris-HCl pH 7.5)

Applications:
Influence on epigenetic markers[1]
Treatment of hepatocellular carcinoma[2]
Treatment of bladder carcinoma[3]
Treatment of lung cancer[4]
Treatment of breast cancer[5]
Treatment of ovarien cancer[6]

Selected References:
[1] Dhayat et al. (2011) Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer- A review. International J. of Cancer 129:1031.
[2] Chua et al. (2011) Targeted therapy in hepatocellular carcinoma. International J. Hepathology 348297:11.
[3] Shelly et al. (2011) Gemcitabine chemotherapy for treatment of metastatic bladder carcinoma. BJU International 108:168.
[4] Hayashi et al. (2011) Gemcitabine:efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer. Clinical Medicine Insights: Oncology 5:177.
[5] Moen et al. (2005) Gemcitabine: in combination with paclitaxel in the first line traetment of metastatic breast cancer. American J. of Cancer 4:327.
[6] Bookmann (2005) Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International J. of Gynecological Cancer 15 Suppl.1:12.